An Introduction to Allergic Diseases
The incidence of respiratory allergies is increasing, particularly in industrialized areas. Allergic inflammation can occur in both the upper and lower airways, and can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying respiratory allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Dermot Ryan, IPCRG 2021: Allergen Immunotherapy in Primary Care
TouchRESPIRATORY got the opportunity to catch up with Dr Dermot Ryan (Asthma UK Centre for Applied Research, The University of Edinburgh, Edinburgh, Scotland) around his presentation on ‘Respiratory Allergy: The Role of Immunotherapy in Primary Care.’ which was presented at The IPCRG 10th World Conference, 6-8 May, 2021. Questions According to current IPCRG guidelines, for which […]
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
Watch a panel of experts discuss the diagnosis of type 2 asthma, the rationale for biological therapy and emerging treatments.
- Recognize the importance of biomarkers to identify patients with type 2 asthma accurately and promptly
- Outline the pathologic pathways underlying type 2 asthma and the differing mechanisms of action of available biologic therapies
- Recall the latest data for biologic therapies in moderate-to-severe type 2 asthma
The role of eosinophils in physiology and disease: Is complete depletion of eosinophils the goal?
Watch Dr Enrico Heffler describe how eosinophilic inflammation can be targeted for the treatment of inflammatory respiratory diseases.
- Understand the dynamics of eosinophils across the human body in wellness and disease
- Discuss clinical scenarios in which eosinophilic therapy may be beneficial
- Recognize how new eosinophilic therapies offer promise for the future treatment of eosinophil-mediated diseases
COVID-19 Pandemic—Allergen-specific Immunotherapy Positioning in Respiratory Allergy
US Respiratory & Pulmonary Diseases. 2020;5(1):10-1 DOI: https://doi.org/10.17925/USPRD.2020.5.1.10
Globally, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected in excess of 55 million people and is associated with over 1.3 million deaths to date (European Centre for Disease Prevention and Control data).1 COVID-19 is placing significant strain on all aspects of routine healthcare and has raised […]
Dupilumab—A Potential New Biologic for Chronic Rhinosinusitis with Nasal Polyps
US Respiratory & Pulmonary Diseases. 2020;5(1):15-7 DOI: https://doi.org/10.17925/USPRD.2020.5.1.15
Chronic rhinosinusitis (CRS) is a clinical syndrome defined by symptomatic inflammation of the paranasal sinuses and nasal cavity for at least 12 weeks in duration. Historically, CRS has been classified into 2 subgroups, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Those with CRSwNP have a more significant burden of disease and poor […]
Call for Submissions 2018
US Respiratory & Pulmonary Diseases, 2017;2(1):Epub ahead of print
US Respiratory & Pulmonary Diseases invites colleagues in the respiratory care and pulmonary disease community to contribute articles for the 2018 edition. US Respiratory & Pulmonary Diseases aims to provide practicing physicians, and related healthcare professionals in the field, with concise and timely articles that provide practical advice and help them in their day-to-day clinical […]
Sublingual Immunotherapy for Respiratory Allergy
European Respiratory and Pulmonary Diseases, 2015;1(1):25–6 DOI: //doi.org/10.17925/ERPD.2015.01.01.25
In the late 1980s, sublingual allergen immunotherapy (SLIT) was proposed as an ‘alternative’ to subcutaneous allergen immunotherapy (SCIT).1,2 The main aim was to reduce systemic reactions and the risk of anaphylaxis, which were frequently associated with SCIT and also to increase the number of patients receiving allergen immunotherapy by facilitating its regular use at home. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!